Pricing Log in Create free account
Saturday 17 October 2026 Export MYGN’s income statement to Excel — free account

Myriad Genetics, Inc.

MYGN Healthcare Diagnostics & Research

Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.98 0.37 −8.51%
Market cap
$416.1M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
5/9
Altman Z
−1.52
Beneish M
−5.42
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.72
Total sells 0.07
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — 1 1 — 1 — — — — —
Sell — — — — — — — 1 — — — —
Insider Ownership 6.54%

Capital & Financial Ratios $m

Market Cap 416.08
Revenue 806.60
Net Income (112.60)
Free Cash Flow (14.20)
Net Debt 5.50
Current Ratio 2.21 (at or above 1.5: strong)
Debt/Equity 0.40 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.01) (negative: loss-making)
P/S ratio 0.47
P/B ratio 1.24
Past 5Y EPS Growth —
This Y EPS Growth (1,300.31%) (below 0%: weak)
Next Y EPS Growth 18.26% (at or above 15%: strong)
Next Y revenue growth (5.66%) (below 0%: weak)
Next 5Y EPS Growth 16.55% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.5×, against a ten-year median of 2.4×; over the ten years it ranged from 0.4× in 2026 to 4.4× in 2018.
P/S against its own 10 years 2.51%
10-year low 10-year high
P/B against its own 10 years 12.75%
10-year low 10-year high
EV/Sales against its own 10 years 3.69%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 141 102 150 115
Receivables 114 121 115 110
Inventory 22 28 31 31
Other — — — —
314 298 333 289
2023 2024 2025 Q'26
Payables 26 32 30 30
ST’ Debt — — — —
Other — — — —
156 164 134 131

Compound Annual Growth %

10y 5y 3y
Sales (0.32%) 3.61% 6.72%
Cash Flow (31.88%) (37.32%) 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.20%) (17.58%) (25.38%)

Revenue $m

Mar Jun Sep Dec Year
’26 200 191 — — —
’25 196 213 206 210 825
’24 202 212 213 211 838
’23 181 184 192 197 753
’22 — — 156 178 678
’22 165 179 — — 678
’21 — — 167 161 691
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (8) — — —
’25 (16) (14) 21 11 2
’24 (19) 3 1 7 (9)
’23 (33) (1) (22) (55) (111)
’22 — — (3) (7) (106)
’22 (46) (50) — — (107)
’21 — — (39) (9) 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (11) — — —
’25 (25) (20) 15 5 (26)
’24 (27) (6) 3 (8) (38)
’23 (57) (20) (40) (68) (184)
’22 — — (20) (22) (152)
’22 (53) (56) — — (107)
’21 — — (42) (13) 1
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.36) (0.46) — — —
’25 0.00 (3.57) (0.29) (0.08) (3.95)
’24 (0.29) (0.41) (0.24) (0.47) (1.41)
’23 (0.67) (1.42) (0.75) (0.36) (3.18)
’22 — — (0.43) (0.52) (1.39)
’22 (0.26) (0.18) — — (1.39)
’21 — — 0.30 (0.10) (0.35)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 15.86 15.15 26.80 20.10 9.24 19.50 13.92 13.82 12.87 3.76

Analyst estimates 2026–2028

Powerpack
High 43.68 37.30 50.44 48.40 30.13 36.95 28.45 24.21 29.30 15.47
People
People Employees 2,206 2,400 2,400 2,600 2,700 2,400 2,600 2,700 2,700 2,700
Revenue/emp, $m 0.34 0.30 0.31 0.00 0.00 0.29 0.26 0.28 0.31 0.31
Income, $m
Income, $m Revenue 741 729 744 851 639 691 678 753 838 825
Gross margin, % 78.76 76.51 76.17 76.38 70.86 71.39 70.22 68.64 69.89 69.93
EBT 156 36 120 0 (223) (57) (141) (262) (123) (395)
EBT margin, % 21.07 4.97 16.15 0.00 (34.97) (8.27) (20.73) (34.81) (14.74) (47.92)
Net income 117 17 133 0 0 (27) (112) (263) (127) (366)
Depreciation 27 48 54 73 172 65 70 62 118 373
Per share, $
Per share, $ Revenue 10.58 10.67 10.72 11.58 8.59 8.85 8.42 9.10 9.25 8.90
Earnings 1.67 0.25 1.92 0.06 (2.69) (0.35) (1.39) (3.18) (1.41) (3.95)
Cash flow 2.38 1.55 1.67 1.14 0.82 0.24 (1.32) (1.34) (0.10) 0.02
Capex (0.07) (0.09) (0.12) (0.12) (0.14) (0.23) (0.56) (0.89) (0.33) (0.30)
Free cash flow 2.30 1.47 1.55 1.02 0.68 0.01 (1.88) (2.22) (0.42) (0.28)
Book value 10.69 11.24 13.92 0.00 11.86 12.41 10.99 9.46 7.74 3.97
Shares, m 70 68 69 74 74 78 81 83 91 93
Valuation, ×
Valuation, × P/E 19.01 80.75 18.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.93 2.41 3.54 2.49 2.30 3.12 1.81 2.09 1.48 0.69
P/B 2.90 2.26 2.72 1.88 1.67 2.22 1.39 2.01 1.77 1.55
EV/Sales 2.72 2.34 3.31 2.61 2.44 2.76 1.86 1.98 1.43 0.73
EV/FCF 8.34 13.70 15.35 25.21 30.83 3,176.67 (8.31) (8.08) (31.18) (23.41)
Cash, $m
Cash, $m Operating cash flow 166 106 116 84 61 19 (106) (111) (9) 2
Capex (5) (6) (8) (9) (10) (18) (45) (73) (30) (27)
Free cash flow 161 100 108 75 51 1 (152) (184) (38) (26)
Balance, $m
Balance, $m Working capital 242 84 225 231 244 281 137 158 134 199
Total debt — 99 9 234 225 79 131 39 40 120
Net debt (159) (52) (171) 97 74 (339) (115) (102) (63) (30)
Shareholders’ equity 748 768 966 1,089 881 968 886 783 701 368
Returns, %
Returns, % ROA 14.23 1.67 11.18 0.59 (14.13) (1.99) (8.90) (22.45) (11.71) (42.20)
ROIC 16.27 3.84 9.59 0.00 (15.16) (18.93) (11.40) (23.63) (12.09) (71.53)
ROE 16.62 2.30 15.37 0.00 (22.18) (2.81) (12.64) (31.55) (17.15) (68.45)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Myriad Genetics, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +29.96% (above 0%: growing) n/m −123.46% (below 0%: shrinking) 21.21% (150.25%) Compare
OPK OPKO Health, Inc. $1.2B — (loss-making) — (loss-making) +4.32% (above 0%: growing) n/m +46.46% (above 0%: growing) 48.92% (4.26%) Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%) Compare
FLGT Fulgent Genetics, Inc. $587.2M — (loss-making) — (loss-making) +4.38% (above 0%: growing) n/m +25.36% (above 0%: growing) 30.07% (42.25%) Compare
MYGN Myriad Genetics, Inc. $416.1M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%)
BDSX Biodesix, Inc. $260.7M — (loss-making) — (loss-making) +34.18% (above 0%: growing) n/m +72.75% (above 0%: growing) 82.06% (20.06%) Compare
XGN Exagen Inc. $207.4M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
BNR Burning Rock Biotech Limited Sponsored ADR $137.1M — (loss-making) 11.1× −4.22% (below 0%: shrinking) n/m +46.01% (above 0%: growing) 72.58% (13.36%) Compare
MDXHF MedX Health Corp. $103.2M — (loss-making) — (loss-making) +33.59% (above 0%: growing) n/m +41.60% (above 0%: growing) 37.19% (1,027.95%) Compare
Median of peers $424.0M — — +18.03% — +43.81% 55.10% (16.71%)

All 52 Diagnostics & Research stocks →

Myriad Genetics, Inc. (MYGN) key facts

  • Concern: Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024.
  • Myriad Genetics, Inc. (MYGN) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MYGN traded at $3.98, a market capitalization of $416.1 million.
  • Return on equity was −68.5% and debt-to-equity 0.40.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −1.52 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Myriad Genetics, Inc. (MYGN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MYGN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com